-
1
-
-
54049120166
-
Drug discovery: are productivity metrics inhibiting motivation and creativity?
-
Ullman F., Boutellier R. Drug discovery: are productivity metrics inhibiting motivation and creativity?. Drug Discov. Today 2008, 13:997-1001.
-
(2008)
Drug Discov. Today
, vol.13
, pp. 997-1001
-
-
Ullman, F.1
Boutellier, R.2
-
2
-
-
67650070045
-
Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds
-
Feng Y., et al. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat. Rev. Drug Discov. 2009, 8:567-578.
-
(2009)
Nat. Rev. Drug Discov.
, vol.8
, pp. 567-578
-
-
Feng, Y.1
-
3
-
-
58049191116
-
Computational approaches in chemogenomics and chemical biology: current and future impact on drug discovery
-
Bajorath J. Computational approaches in chemogenomics and chemical biology: current and future impact on drug discovery. Exp. Opin. Drug Discov. 2008, 3:1371-1376.
-
(2008)
Exp. Opin. Drug Discov.
, vol.3
, pp. 1371-1376
-
-
Bajorath, J.1
-
4
-
-
68149160053
-
Physicochemical drug properties associated with in vivo toxicological outcomes: a review
-
Price D.A., et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Exp. Opin. Drug Metab. Toxicol. 2009, 5:921-931.
-
(2009)
Exp. Opin. Drug Metab. Toxicol.
, vol.5
, pp. 921-931
-
-
Price, D.A.1
-
5
-
-
64249155573
-
Aleglitazar, a new, potent, and balanced dual PPAR alpha/gamma agonist for the treatment of type II diabetes
-
Benardeau A., et al. Aleglitazar, a new, potent, and balanced dual PPAR alpha/gamma agonist for the treatment of type II diabetes. Bioorg. Med. Chem. Lett. 2009, 19:2468-2473.
-
(2009)
Bioorg. Med. Chem. Lett.
, vol.19
, pp. 2468-2473
-
-
Benardeau, A.1
-
6
-
-
67649839953
-
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
-
Henry R.R., et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135.
-
(2009)
Lancet
, vol.374
, pp. 126-135
-
-
Henry, R.R.1
-
7
-
-
84889816308
-
-
Strategies for the cytosolic delivery of macromolecules: an overview. In Handbook of Pharmaceutical Biotechnology,
-
Asokan, A. et al. (2007) Strategies for the cytosolic delivery of macromolecules: an overview. In Handbook of Pharmaceutical Biotechnology, pp. 279-296.
-
(2007)
, pp. 279-296
-
-
Asokan, A.1
-
8
-
-
43149103943
-
Targeting RNA with small molecules
-
Thomas J.R., Hergenrother P. Targeting RNA with small molecules. Chem. Rev. 2008, 108:1171-1224.
-
(2008)
Chem. Rev.
, vol.108
, pp. 1171-1224
-
-
Thomas, J.R.1
Hergenrother, P.2
-
9
-
-
65349105337
-
Using small molecules to great effect in stem cell differentiation
-
Zaret K.S. Using small molecules to great effect in stem cell differentiation. Cell Stem Cell 2009, 4:373-374.
-
(2009)
Cell Stem Cell
, vol.4
, pp. 373-374
-
-
Zaret, K.S.1
-
10
-
-
54249155522
-
Network pharmacology: the next paradigm in drug discovery
-
Hopkins A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4:682-690.
-
(2008)
Nat. Chem. Biol.
, vol.4
, pp. 682-690
-
-
Hopkins, A.L.1
|